A confirmatory, randomized, placebo-controlled, double-blind, multicenter trial to assess the efficacy of CEREBROLYSIN in post-acute ischemic stroke recovery (CARS-CT)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521350-41-01

Acronym

FSNANO28012025

Enrollment

416

Registered

2025-07-07

Start date

2025-10-10

Completion date

Unknown

Last updated

2025-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Brief summary

Action Reasearch Arm Test (ARAT)

Detailed description

NIH Stroke Scale (NIH), Modified Rankin Scale (mRS), Barthel Index, Hospital Anxiety and Depression Scale (HADS), EQ-5D-5L

Interventions

DRUGCEREBROLYSIN

DRUGSer fiziologic 90 mg/10 ml solvent pentru uz parenteral

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Action Reasearch Arm Test (ARAT)	—

Secondary

Measure	Time frame
NIH Stroke Scale (NIH), Modified Rankin Scale (mRS), Barthel Index, Hospital Anxiety and Depression Scale (HADS), EQ-5D-5L	—

Countries

Romania

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026